Many companies enter the market with OTC products expecting a faster and simpler regulatory pathway—but quickly run into unexpected complexity. Even a single over-the-counter (OTC) product must meet strict requirements for safety, quality, and correct patient use without medical supervision, which regulators assess very carefully.
The problem is that this complexity is often underestimated. Companies move forward without a clear regulatory affairs strategy, only to face classification issues, inconsistent requirements across EU markets, and delays caused by incomplete or misaligned documentation . What initially looked like a straightforward process becomes fragmented, slow, and difficult to manage internally.
This creates real pressure—timelines slip, costs increase, and teams are forced into reactive decision-making instead of structured development. And the biggest risk? Choosing the wrong support for your OTC products can mean reworking entire parts of your OTC product strategy.
That’s why the question is no longer whether you need a regulatory consultant or an OTC consultant—but how to choose the right one before costly mistakes happen.
How to choose an OTC consultant for OTC products in a fragmented EU landscape
When companies start thinking about how to choose a regulatory consultant or an OTC consultant for OTC products, they often underestimate what they are actually dealing with. The challenge is not just regulatory—it is structural. Every OTC product must first be assessed and classified at a national level, and that classification can differ significantly from one EU country to another, even for the same product.
This means there is no single, universal pathway for OTC products. Instead, companies must navigate a patchwork of regulatory expectations, where safety data, labeling requirements, and market access conditions can shift depending on the target country. Without a clear regulatory affairs consulting approach, this quickly leads to inconsistent decisions, duplicated work, and delays that could have been avoided.
That is why choosing the right OTC consultant is not about support—it is about control. A capable partner must be able to interpret this fragmented environment, translate it into a coherent regulatory pathway, and guide your OTC product from development to approval without unnecessary detours. Regulatory affairs acts as the bridge between companies and authorities, translating requirements into practical actions across the product lifecycle .
If they cannot do that, they are not simplifying the process—they are becoming part of the complexity you are trying to solve.
How Billev Pharma East helps you succeed as your OTC consultant for OTC products
When companies struggle with OTC products, the issue is rarely a lack of effort—it is a lack of structure. Regulatory requirements are understood in theory, but translating them into a clear, executable pathway for each OTC product is where most teams fail.
This is exactly where Billev Pharma East acts as your OTC consultant and makes the difference. Instead of treating regulatory as a fragmented set of activities, we build a unified strategy that connects development, classification, documentation, and submission into one consistent pathway. From the earliest phase, we define a regulatory approach that aligns with both EU expectations and your business goals, ensuring that your OTC products move forward without unnecessary delays.
What sets us apart is not only strategy, but execution. We also support regulatory outsourcing, allowing companies to extend their internal capabilities and ensure continuity across critical phases, from dossier preparation to authority interactions. We work directly with EU national competent authorities and the EMA, managing interactions, preparing dossiers, and ensuring that every step is aligned with real regulatory expectations—not assumptions.
At the same time, our model is built to support the full lifecycle of your OTC product. We combine regulatory affairs, pharmacovigilance, medical consultancy, and quality systems into one integrated service, removing fragmentation and reducing risk across the entire process.
The result is simple but critical: your OTC products are no longer managed reactively. They are guided by a structured, proactive strategy—one that accelerates approval, minimizes rework, and gives you full control over your path to market.
How to structure your decision process for OTC products before engaging an OTC consultant
Before selecting support or engaging an OTC consultant, companies working with OTC products should first understand that regulatory success depends on how early decisions are structured. An OTC product is not simply “non-prescription”—it must meet strict criteria for classification, including well-known active substances, proven safety, and suitability for short-term, self-managed use .
This means that preparation is not about collecting documents, but about defining the logic behind your product: how it will be positioned, how risks are mitigated, and how it fits within different national frameworks where classification decisions are made independently .
Companies that take the time to structure this thinking upfront are able to engage a consultant more effectively—because they are not asking basic questions, but making informed, strategic decisions about their OTC products from the start.
What mistakes to avoid when selecting an OTC consultant for OTC products
One of the biggest risks in OTC products development is not regulatory complexity itself—but the wrong decisions made early, especially when choosing support for your OTC product.
A common mistake is assuming that all regulatory consultants or OTC consultants are interchangeable.. In reality, OTC is a highly specific area where classification, labeling, and patient self-use must all be justified, and this varies significantly across EU countries . A consultant without direct OTC experience may follow a generic approach that simply does not work in practice.
Another issue is choosing based on availability or cost instead of capability. Regulatory for OTC products is tightly linked to EU legislation that requires full demonstration of safety, quality, and efficacy before market access. If a consultant cannot align strategy with these requirements from the beginning, companies often face delays, additional data requests, or even the need to repeat parts of development.
There is also a tendency to separate strategy from execution. Some consultants define a pathway but are not involved when real regulatory challenges arise—during authority interactions or dossier preparation. This creates a disconnect, where decisions made early cannot be properly implemented later.
Finally, companies often underestimate how critical classification is. Each OTC product must be formally classified at a national level, and even small differences in positioning can change the entire regulatory pathway . Without the right expertise, this becomes a trial-and-error process.
Avoiding these mistakes is not about perfection—it is about choosing a partner who understands that with OTC products, every early decision has long-term consequences.
If you want to avoid rework, delays, and missed market opportunities, the decision is clear. You need an OTC consultant who combines strategy, execution, and ownership—someone who can take your OTC product from concept to approval with confidence.
Read also:
- How to choose biotech regulatory consulting for Series A biotech companies
- Alternatives to big Pharma RA consultancies: why regulatory affairs consulting needs a smarter approach
- Regulatory updates: EMA Enhances SPOR and XEVMPD Data Management Landscape
Sources: 1 – European Commission. (n.d.). Legal framework governing medicinal products for human use in the EU, 2 – AESGP. (n.d.). Non-prescription medicines (OTC medicines), 3 – European Commission. (2006). Guideline on changing the classification for the supply of a medicinal product for human use, 4 – European Directorate for the Quality of Medicines & HealthCare. (n.d.). Classification of medicines as regards their supply, 5 – López Vila, E. D., Buts, C., & Jegers, M. (2023). A quantitative classification of OTC medicines regulations in 30 European countries. Journal of Pharmaceutical Policy and Practice.
Image credits:
In-article images: Designed by Freepik
Hero image: Designed by Freepik